Other grades of this product :
| SNS-032 Basic information |
| Product Name: | SNS-032 | | Synonyms: | BMS-387032; SNS 032; SNS032; BMS 387032; BMS387032;CS-202;SNS 032; SNS032; SNS-032; BMS387032; BMS 387032; BMS-387032;BMS-3870032
N-[5-[(5-tert-Butyl-1,3-oxazol-2-yl)methylsulfanyl]-1,3-thiazol-2-yl]piperidine-4-carboxamide;N-[5-[(5-tert-Butyl-1,3-oxazol-2-yl)methylsulfanyl]-1,3-thiazol-2-yl]piperidine-4-carboxamide SNS-032 (BMS-387032);N-[5-[(5-tert-butyl-1,3-oxazol-2-yl)methylsulfanyl]-1,3-thiazol-2-yl]piperidine-4-carboxamid;SNS-032, >=99%;SNS-032, 98.5%, a selective CDK2 inhibitor | | CAS: | 345627-80-7 | | MF: | C17H24N4O2S2 | | MW: | 380.53 | | EINECS: | | Product Categories: | Inhibitors;Specific and potent inhibitor of cyclin-dependent kinases (CDK) 2, 7 and 9.;Aromatics;Heterocycles;Intermediates & Fine Chemicals. Sulfur & Selenium Compounds;Pharmaceuticals;Inhibitor of cyclin-dependent kinases (CDK) 2, 7 and 9. | | Mol File: | 345627-80-7.mol |
| SNS-032 Chemical Properties |
| Melting point | 171-173 °C | | density | 1.28±0.1 g/cm3(Predicted) | | storage temp. | under inert gas (nitrogen or Argon) at 2–8 °C | | solubility | DMSO (Slightly), Methanol (Slightly) | | form | Solid | | pka | 7.33±0.70(Predicted) | | color | White to Off-White |
| SNS-032 Usage And Synthesis |
| Description | Cyclin-dependent kinases (CDKs) are key regulators of cell cycle progression and are therefore promising targets for cancer therapy. SNS-032 is an ATP-competitive inhibitor of Cdk9, 2, and 7 with IC50 values of 4, 38, and 62 nM, respectively. It is selective for these kinases and displays no additional activity against a panel of 190 kinases (IC50s = >1,000 nM). SNS-032 can block the cell cycle, inhibit transcription, and induce apoptosis in multiple myeloma RPMI-8226 cells with an IC90 value of 0.3 μM. This compound has been shown to induce apoptosis by inhibiting the transcription of the anti-apoptotic proteins, Mcl-1 and XIAP. | | Chemical Properties | Off-White Solid | | Uses | SNS 032 is a selective inhibitor of Cyclin-dependent Kinase (CDK) 2,7, and 9. | | references | [1]. tong w.g., chen r., plunkett w., et al. phase i and pharmacologic study of sns-032, a potent and selective cdk2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myeloma. journal of clinical oncology, 2010, 28(18):3015- 3022.[2]. chipumuro e., marco e., christensen c.l., et al. cdk7 inhibition suppresses super-enhancer-linked oncogenic transcription in mycn-driven cancer. cell, 2014, 159:1-14.[3]. meng h., jin y.m., liu h., et al. sns-032 inhibits mtorc1/mtorc2 activity in acute myeloid leukemia cells and has synergistic activity with perifosine against akt. journal of hematology & oncology, 2013, 6:18.[4]. chen r., wierda w.g., chubb s., et al. mechanism of action of sns032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia. blood, 2009, 113(19):4637-4645. |
| SNS-032 Preparation Products And Raw materials |
|
日本语
한국어
Français
Deutsch
España
Türkiye